Alzheimers disease dementia
Conditions
Interventions
None listed
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with Alzheimer's disease (AD) dementia: -Diagnosis of dementia of the AD type (McKhann et al. 2011) -Age > 55 years -Mentally competent (MMSE>=18) and able to give informed consent -Informed consent before participation in the study Patients with Mild cognitive impairments (MCI) or Subjective cognitive impairment (SCI): -Diagnosis of MCI (Albert et al. 2011) or diagnosis of Mild Neurocognitive Disorder (DSM V) (Sachs-Ericsson and Blazer 2015) or diagnosis of SCI as given by the memory clinic (SCI is defined by an individual experiencing subjective complaints and visiting the memory clinic for these complaints, but not showing a significant decline in objective cognitive assessment) -Age > 55 years -Mentally component (MMSE >=18) and able to give informed consent -Informed consent before participation in the study Control subjects: -Mini-Mental State Examination (MMSE) >= 26 -Age > 55 years -Mentally component (MMSE >=18) and able to give informed consent -Informed consent before participation in the study
Exclusion criteria
Exclusion criteria: - Any significant disease or unstable medical condition that could influence neuropsychological testing (with the exception of a SCI, MCI or AD diagnosis) - Major depression (according to the DSM IV) (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - To determine group differences on glymphatic metrics (ISF, pulsatility) between the patient groups (AD, MCI, SCI) and cognitively normal control subjects. - To determine the relation between glymphatic metrics (ISF, pulsatility), neurodegeneration and lower cognitive performance. | — |
Secondary
| Measure | Time frame |
|---|---|
| - To determine the association between ISF characteristics, arterial pulsatility and demographical data, data on sleep and physical activity. - To determine the association of MRI derived glymphatic metrics, brain tissue markers and functional cerebral networks - To determine the associations of glymphatic metrics and biochemical markers of Alzheimer*s disease - To determine the relation between physiological measures of autonomous nervous system functioning, glymphatic metrics and lower cognitive performance. - To determine if there are any changes in the relationship between glymphatic metrics and cognitive performance in healthy controls over time | — |
Countries
Netherlands
Outcome results
None listed